Can a drug stop dangerous side effects of new myeloma therapies?
Disease control
Recruiting now
This phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatm…
Phase: PHASE2 • Sponsor: Naresh Bumma • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC